Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness

Dobromir Dimitrov1,3*, Marie-Claude Boily2, Elizabeth R. Brown1,4, Timothy B. Hallett2

1 Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 2 Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, United Kingdom, 3 Department of Applied Mathematics, University of Washington, Seattle, Washington, United States of America, 4 Department of Biostatistics, University of Washington, Seattle, Washington, United States of America

Abstract

Background: Four clinical trials have shown that oral and topical pre-exposure prophylaxis (PrEP) based on tenofovir may be effective in preventing HIV transmission. The expected reduction in HIV transmission and the projected prevalence of drug resistance due to PrEP use vary significantly across modeling studies as a result of the broad spectrum of assumptions employed. Our goal is to quantify the influence of drug resistance assumptions on the predicted population-level impact of PrEP.

Methods: All modeling studies which evaluate the impact of oral or topical PrEP are reviewed and key assumptions regarding mechanisms of generation and spread of drug-resistant HIV are identified. A dynamic model of the HIV epidemic is developed to assess and compare the impact of oral PrEP using resistance assumptions extracted from published studies. The benefits and risks associated with ten years of PrEP use are evaluated under identical epidemic, behavioral and intervention conditions in terms of cumulative fractions of new HIV infections prevented, resistance prevalence among those infected with HIV, and fractions of infections in which resistance is transmitted.

Results: Published models demonstrate enormous variability in resistance-generating assumptions and uncertainty in parameter values. Depending on which resistance parameterization is used, a resistance prevalence between 2% and 44% may be expected if 50% efficacious oral PrEP is used consistently by 50% of the population over ten years. We estimated that resistance may be responsible for up to a 10% reduction or up to a 30% contribution to the fraction of prevented infections predicted in different studies.

Conclusions: Resistance assumptions used in published studies have a strong influence on the projected impact of PrEP. Modelers and virologists should collaborate toward clarifying the set of resistance assumptions biologically relevant to the PrEP products which are already in use or soon to be added to the arsenal against HIV.

Introduction

Several randomized clinical trials demonstrated that if used adequately, pre-exposure prophylaxis (PrEP); products in the form of daily pills (oral PrEP) or topical gels (vaginal microbicides) could be partially effective in preventing HIV acquisition for men who have sex with men [1], heterosexual men and women [2,3], and serodiscordant couples [4]. Although these encouraging results were not confirmed in two other trials [5,6], Truvada (emtricitabine/tenofovir disoproxil fumarate) became the first drug approved for PrEP use in US [7]. Guidelines for the safe use of PrEP by MSM and heterosexual active adults have recently been published by the Center for Diseases Control (CDC) and the Southern African HIV Clinicians Society [8–10]. PrEP products could therefore add to the HIV prevention options available to both state and local health officials, who then decide how best to allocate resources.

Mathematical models are increasingly being used to assess the potential public health impact of oral or topical PrEP interventions for specific regions or populations in order to better understand when they can be most useful [11–30]. One of the greatest concerns for the successful addition of antiretroviral (ARV) based PrEP to HIV prevention programs is that infected individuals who use PrEP, because they are either unaware of their serostatus or...
become HIV-positive after starting to use the product, may acquire drug resistance (ADR) and thus increase the risk of transmitting drug resistance (TDR). Currently, little resistance was reported in the completed clinical trials, which may be at least partly because the trials were of short duration and because PrEP users were frequently monitored and taken off treatment soon after seroconversion, probably much sooner than would likely happen in real life.

Of all modeling studies assessing the effectiveness of PrEP published before 2012 [11–30], only a few discussed the possible spread of drug resistance and its influence on the success of PrEP interventions. These mathematical models use a broad range of assumptions and parameter values to reflect the mechanisms of drug-resistance (e.g. the rate of emergence of drug resistance among HIV positive individuals who use PrEP, infectiousness of resistance carriers, rate of resistance reversion following PrEP discontinuation, and PrEP efficacy against drug-resistant HIV infection). In addition, modeling studies examine various PrEP intervention scenarios in different HIV epidemics and populations, often using study-specific indicators and time frames to assess the benefits and risks associated with PrEP use. Therefore, differences in the projected population-level impact of PrEP use across models are difficult to understand, even in in-depth reviews [31]. Depending on the combination of assumptions used, some modeling studies suggest that the emergence of drug resistance may lead to a greater reduction in overall HIV incidence.

The HIV Modeling Consortium, which aims to help improve scientific support for decision making by co-coordinating a wide

---

**Table 1. Parameters and ranges used in the analysis.**

| Parameter | Description | Values and ranges | Ref. |
|-----------|-------------|-------------------|------|
| A. Behavioral and epidemic parameters (pre-intervention) | | | |
| $\beta_w$ | Female HIV acquisition risk per vaginal act | 0.0019–0.0046 | [38] |
| $\beta_m$ | Male HIV acquisition risk per vaginal act | (50–100%) of $\beta_w$ assumed [38] | |
| $1/\mu$ | Average time to remain sexually active | 35 years [39,40] | |
| $d_r, d$ | HIV-related mortality rates of people infected with resistant and wild-type HIV | 8.3%–14.3% [41,42] | |
| $n_{w,m}$ | Average number of sexual acts per year for women and men | 60–100 [43,44] | |
| $r_{w,m}$ | Average number of sexual partners per year for women and men | 0.5–1.5 [44–45] | |
| $c$ | Rate of condom use in general population as a fraction of sex acts in which a condom is used | 20–60% | |
| $\sigma_c$ | Condom efficacy per sex act | 0.8–0.95 [46] | |
| B. Calibrated epidemic data | | | |
| $P_w$ | Initial HIV-prevalence (women) | 20% | [36] |
| $P_m$ | Initial HIV-prevalence (men) | 15% | [36] |
| Inc | Fitted HIV-incidence (total) | 0.6–2.5% | [37] |
| $P_{t5}$ | Fitted HIV-prevalence in 5 years (total) | 16.5%–18.5% assumed | |
| C. Intervention parameters | Baseline value | | |
| $k$ | PrEP coverage. Proportion of men and women who use PrEP | 50% assumed | |
| $k_1$ | Initial fraction of the susceptibles using PrEP | 50% assumed | |
| $a_s$ | PrEP efficacy in reducing susceptibility per act when exposed to wild-type HIV | 50% assumed | |
| $a_i$ | PrEP efficacy in reducing infectiousness per act wild type when exposed to wild-type HIV | 50% assumed | |
| $\gamma$ | PrEP adherence | 100% assumed | |
Table 2. Resistance-related parameters used in the analysis.

| Description (symbol) | Parameters sets extracted from published papers | Baseline value |
|----------------------|-----------------------------------------------|----------------|
| Rate of resistance development by full adherers to PrEP (r) | P 1 [19] P 2 [23] P 3 [25] P 4 [26] P 5 [21] P 6 [15] P 7 [24] | 0–2 0–2 0.5–1 2.6–27.6 0.1–1 0.5–1 2–6 3 (1–5) |
| Prescription rejection rate (h) | 0 0–1 0.1–0.7 1 1 1 0.75–0.95 75% (50%–100%) |
| Annual PrEP dropout rate by HIV-positive individuals (d) | 0 0–1 2–4 2–333 0.33–2 1 0.33–2 1 (0.33–3) |
| Rate of resistance reversion for HIV-positive former PrEP users who acquired drug resistance when on PrEP (t) | 0 0 0–4 1–4 2–12 1–12 1–12 4 (2–6) |
| Rate of resistance reversion for HIV-positive non-users of PrEP to whom the resistant HIV has been transmitted (1) | 0 0 0–4 0.07–0.5 0.07–0.5 2–12 0.2–1 0.3 (0.1–0.5) |
| Probability to transmit resistant over wild-type HIV by infected individuals with ADR (e) | 1 1 1 1 1 0.2–1 0.5–1 75% (50–100%) |
| Probability to transmit resistant over wild-type HIV by infected individuals with TDR (1) | 1 1 1 1 1 0.5–1 0.75–1 87.5% (75–100%) |
| Relative infectiousness of individuals infected with resistant HIV (b) | 1 1 1 0–0.5 0–0.5 0–0.5 0–0.25 50% (0–100%) |
| Relative PrEP efficacy when exposed to resistant compared to wild type HIV (c) | 1 1 1 0–0.5 0–0.5 0–0.5 0–0.5 50% (0–100%) |

No values are provided in the paper. The range from the more recent paper [24] of the same research group is used.

In this paper, we extend the narrative review by Baggaley et al [31] and investigate, with a mathematical model, the independent and combined effects of key resistance assumptions from previously published studies on the outcomes of oral PrEP interventions. We focus on understanding the extent to which ignoring the development and spread of resistance influences modeling results, under a variety of epidemic conditions. We also identify conditions under which drug resistance may cause an increase in the projected number of prevented infections due to PrEP use.

**Methods**

**Transmission model**

We developed a compartmental mathematical model of HIV transmission in a heterosexual population (age 15–49) to study the influence of drug resistance on the impact of PrEP (Figure 1). The individuals in the simulated population are aggregated in compartments for men (subscript g = m) and women (subscript g = w), by PrEP status as users (superscript p) and nonusers, and by HIV status as susceptible (S), infected with wild-type HIV (I), infected with drug-resistant HIV through transmission (subscript R), individuals who developed (acquired) resistance while using PrEP (subscript r) and AIDS (A). HIV susceptible men and women who become sexually active join the community at constant rates, and are selected to balance the departure rate in an uninfected population. The rates at which men and women acquire HIV-infection, i.e., forces of infection for different classes, are derived from standard binomial models based on the annual number of partners per susceptible person, the number of sex acts per partnership, the fraction of sex acts protected by condoms, and the HIV acquisition risk per vaginal act for men and women, which may depend on resistance status of the infected partner at the time of exposure (wild type vs. drug-resistant carrier). A fraction of the initial and newly recruited population is assumed to be PrEP users. When PrEP is used by one or both partners in a serodiscordant contact, the acquisition risk of the susceptible partner is influenced by the protection per sex act provided by PrEP (PrEP efficacy) as described below. PrEP users may undergo initial and subsequent periodic HIV testing at different frequencies. They strictly follow the prescribed daily regimens but are removed from PrEP if tested positive for HIV. The efficacy of PrEP is allowed to vary for resistant infections as described in one of the next sections. A complete description of the model is given in File S1.

**PrEP efficacy and intervention coverage**

The results from the concluded clinical trials suggest that when used consistently, oral PrEP provides partial protection against HIV acquisition and therefore reduces the susceptibility of the users [1,3,4]. It is also theoretically plausible that infected individuals who continue to use ARV-based PrEP will have a reduced viral load and therefore a lower risk of transmitting HIV to their uninfected partners. Studies of tenofovir use by HIV-positive individuals have associated it with low-level viremia [33–35], and support the potential role of PrEP in reducing infectiousness incorporated in some of the published modeling
Influence of Resistance Assumptions on PrEP Impact

Assumption on drug resistance due to ARV PrEP

Consistent PrEP use after HIV acquisition or initiating PrEP in already infected individuals may lead to emergence of acquired drug resistance (ADR), which may subsequently be transmitted to ARV-naive individuals (transmitted drug-resistance, TDR). We reviewed 20 studies, published before 2012, which evaluated the impact of oral or topical PrEP with dynamic mathematical models [11–30], and focused on the studies which addressed drug resistance due to PrEP [15,19,21,23–26]. Three of the selected studies simulate interventions of topical PrEP [19,23,25] while the other four investigate interventions of oral PrEP [15,21,24,26]. We extracted the modeling and parameter assumptions regarding the emergence, persistence and transmission of drug resistance due to PrEP implemented in these models. Our model, which represents oral PrEP, was designed to accommodate key resistance-related mechanisms and assumptions used in the previous published analyses in order to compare their influence. The list includes assumptions regarding the efforts to restrict the access of infected individuals to PrEP, which could be managed during real-time interventions by:

- Restricting the opportunities of already infected individuals to start using PrEP. Prescription rejection rate ($\theta$) represents the actual reduction in new PrEP prescriptions issued to infected compared to susceptible individuals. If the access to PrEP is not controlled ($\theta = 0$), then the same proportion of infected and susceptible people initiate PrEP. Conversely, if the access to PrEP is under strict control ($\theta = 1$), then no infected individuals start using PrEP.
- Removal of the HIV-positive PrEP users from PrEP as a result of periodic HIV screening. Annual PrEP drop-rate ($\delta$) represents the rate at which infected PrEP users stop taking their pills. It is reciprocal to the average time to remain on PrEP after HIV acquisition. For instance, if $\delta = 0.5$ people who acquire HIV when on PrEP continue to take their pills for an average of two years.

The rest of the modeling assumptions are related to the natural history of resistance in an infected host using PrEP:

- Consistent use of oral PrEP by infected individuals leads to emergence of drug resistance at rate $r$. The resistance rate is reciprocal to the average time needed to develop resistance while infected with HIV and using PrEP;
- Resistance carriers may be less infectious than those infected with wild-type HIV (relative infectiousness $\beta_r$) due to the reduced fitness of the resistant compared to wild-type HIV. Relative infectiousness of 50% ($\beta_r = 0.5$) implies that it is half as likely to acquire HIV during contact with a partner infected with resistant HIV;
- Probabilities to acquire resistant HIV through transmission, given that the transmission occurs, may be different for contacts with partners infected with TDR ($\gamma_T$) and ADR ($\gamma_A$);
- The dominance of resistant HIV in an infected host may revert back to wild type when PrEP is not used. The reversion rate may be substantially slower in ARV-naive hosts with TDR (reversion rate $\tau_T$) compared to former PrEP users who developed ADR when on PrEP (reversion rate $\tau_A$). For instance, ADR may revert back over three months after PrEP use is interrupted ($\tau = 4$), while it may take four years to lose detectable TDR ($\tau_T = 0.25$);
- PrEP may provide reduced protection when susceptible users are exposed to drug-resistant compared to wild-type HIV (relative PrEP efficacy $\gamma_T$). A relative PrEP efficacy of 50% ($\gamma_T = 0.5$) implies that PrEP is half as effective per sex act with a partner infected with resistant HIV compared to an act with a partner infected with wild-type HIV.

We have compiled a list of the ranges of resistance-related parameters used in the published papers which include resistance (see Table 2). To help interpret results across studies, we analyzed the model outcomes using 10,000 parameter combinations, randomly sampled from the set extracted from each study. An aggregated parameter set (Table 2, last column), which combines the ranges from all studies, is used when the impact of resistance factors is evaluated in multivariate sensitivity analysis.

Epidemic settings and intervention scenarios

Demographic, behavioral and epidemic parameters were defined and initially sampled from ranges representative of the HIV epidemics in the Sub-Saharan region (see Table 1, part A). Next, we identified 1,000 posterior parameter sets, reflecting prototypical hyper endemic in southern Africa using the following target criteria (see Table 1, part B): i) initial HIV prevalence of 15% and 20% among 15–49 years old men and women, respectively [30]; ii) annual incidence rate between 0.6% and 2.5% [37]; iii) female incidence rate at least 30% higher than male incidence rate [37]; and iv) the absolute difference in HIV prevalence over five years remains below 1% (mature epidemics).

With the selected epidemic parameters we simulate: i) an HIV epidemic without PrEP use; ii) an HIV epidemic with PrEP use but without drug resistance due to PrEP; and iii) an HIV epidemic with PrEP use assuming emergence of drug resistance due to PrEP. The impact of the PrEP interventions is measured in terms of the cumulative fraction of infections prevented (CPF), the cumulative fraction of infections in which drug-resistant HIV is transmitted (TRF), and the resistance prevalence (RP) among HIV-positive individuals, all evaluated over ten years of PrEP use. The choice of epidemic sets has little influence on the intervention outcomes. Results from simulations in which only epidemic and resistance parameters are varied while the other parameters remain fixed are presented in the Supporting Information (see Fig. S2 in File S1). To delineate the influence of the resistance on the projected PrEP effectiveness we evaluate the relative CPF, defined as the ratios of CPF for scenarios with resistance over scenarios without resistance:
Relative CPF

Values of the relative CPF greater than one indicate that the addition of resistance improves the CPF. The contribution of the resistance to the PrEP effectiveness is measured by the relative change in the projected CPF under scenarios with and without resistance:

Contribution to CPF = 1 - \frac{CPF (PrEP without resistance)}{CPF (PrEP + resistance)}

This metric estimates what fraction of the CPF can be attributed to the resistance. The contribution of the resistance is positive (i.e., reduce HIV incidence) when the relative CPF is greater than one.

The influence of resistance parameters on key intervention outcomes (relative CPF and resistance prevalence after ten years of PrEP use) is studied in a multivariate sensitivity analysis. Partial rank correlation coefficients (PRCC) are calculated for each parameter-outcome pair to evaluate the impact of parameter variation on the monotonicity of the outcome. The analysis is based on 10,000 simulations using randomly sampled resistance parameters and intervention parameters fixed on their baseline values from Table 1, part C. Additional sensitivity analysis results are presented in the Supporting Information (see Fig. S3 in File S1).

Results

Summary of resistance assumptions from the review of published PrEP models

The resistance parameters used in the published modeling studies demonstrate enormous variability in assumptions and uncertainty in values (see Table 2). All the papers (except [19]) include activities to reduce the PrEP use by infected individuals (positive prescription rejection rate \( h \) and drop rate \( d \)). However, some studies assume “susceptible only” access to PrEP (\( h = 1 \)) [15,21,26], while others [23,25] explore wide ranges corresponding to interventions with unrestricted access (\( h = 0 \)) to “susceptible only” access (\( h = 1 \)). The rates at which infected PrEP users acquire resistance (r) also vary substantially across studies. The range explored in [19,23] suggests that it takes from six months to indefinitely longer for resistance to develop, while the same time is estimated at between one and six months in [24,26]. The majority...
of the studies (all except [19] and [23]) allow for the resistant HIV to revert back to wild-type HIV when PrEP is not used, with four of the models differentiating the reversion rates for acquired and transmitted resistance [15,21,24,26]. Five of the models assume that the carriers of resistance transmit only resistant HIV [19,21,23,25,26], while the remaining two allow also for wild-type HIV to be transmitted with probability of up to 50% and 80%, respectively. All published models agree that the infectiousness of the resistance carriers will be decreased due to fitness loss of the resistant HIV, but the reduced levels explored in each paper are fundamentally different. Only four of the studies consider the possibility that PrEP will provide limited protection against resistant HIV [15,21,24,26].

**Figure 3. Impact of the relative PrEP efficacy \( c_r \), 0 – no protection, 1 – equal protection) when exposed to drug-resistant compared to wild type HIV and the relative infectiousness (\( b_r \), 0 – not infectious, 1 – equally infectious) of individuals infected with drug-resistant compared to wild-type HIV on the resistance contribution to the cumulative fraction of infections prevented (CPF) over 10 years.**

A) Contour plots of the relative CPF with all resistance parameters, except \( c_r \) and \( b_r \), fixed on their baseline values from Table 2 (last column). Values less than one (shaded region) indicate that resistance impacts negatively the estimate of the CPF. Blue dots represent the median value of \( c_r \) and \( b_r \) from the parameter sets defined in Table 2; and B) Simulations with positive (red) and negative (blue) resistance contributions using resistance parameters randomly sampled from the ranges in Table 2 (last column); Relative CPF is calculated as the ratio of the 10-year CPF for scenarios with resistance over baseline scenario (no resistance).

doi:10.1371/journal.pone.0080927.g003

**Figure 4. Partial rank correlation coefficients (PRCC) between resistance-related parameters and intervention outcomes, relative 10-year CPF (green) and resistance prevalence after 10 years (blue) based on 10,000 simulations (10 per preselected epidemic set).** The intervention parameters are fixed on their baseline values from Table 1, part C. Relative CPF is calculated as the ratio of the 10-year CPF for scenarios with resistance over baseline scenario (no resistance).

doi:10.1371/journal.pone.0080927.g004

**Contribution of drug resistance to the population-level PrEP impact**

Figure 2 shows the impact of resistance on the predicted PrEP benefits (ten-year CPF) and PrEP risks (RP and TRF) using resistance parameters from different modeling studies. The influence of resistance on the number of infections prevented varied considerably across studies despite the same behavioral, epidemic and intervention conditions. The projected ten-year CPF varied between 32% and 62% (Fig. 2A), the predicted resistance prevalence among infected individuals varied between from 2% to 44% (Fig. 2B), and the infections in which resistance is transmitted varied between 1% and 8% (Fig. 2C). The two sets (P1 and P2)
that produce the most optimistic predictions in terms of CPF (43%–62%) also predict the largest resistance prevalence (20%–44%). If the model is parametrized with the set P1, the resistance has a substantial contribution (a median of 18%) to the PrEP effectiveness, which translates into up to 11% of the total HIV infections additionally prevented due to resistance over ten years (Fig. 2D). In contrast, the model using parameter sets P4–P7 projects only 32%–33% infections prevented over ten years, with a minimal variation due to the resistance assumptions. Note that the resistance prevalence due to PrEP with the parameter set P5 remains below 1% in 97.5% of the simulated epidemics, while the results obtained with set P7 predict approximately the same reduction in HIV infections over ten years, but a larger proportion of resistance among HIV-positive individuals (up to 7% in some simulations). Under the parameterization with P4 resistance still adds to CPF (its contribution is up to 5%), while the simulations using P7 show negative contribution of resistance to CPF, i.e., actual reduction of CPF by up to 10%.

The magnitude of the resistance contribution (positive or negative) is limited when stronger restrictions on PrEP use by HIV positive individuals are imposed. All sets except P1 incorporate restricted access to PrEP (positive prescription rejection rates 0 and PrEP drop rates δ) for infected individuals, but the stronger control assumed in the sets P4–P7 (0 near 1 and large δ) leads to a substantially smaller number of infected people who use PrEP, i.e., being at risk of emerging resistance. Another factor limiting resistance effects is the reversion of the resistant HIV back to wild-type after the interruption of PrEP use. It is included in all sets except P1 and P2 (positive τ and τd). The faster reversion assumed in sets P4–P7 implies short persistence of resistance when PrEP is not used, and smaller influence of the resistance on the intervention outcomes.

The large uncertainty in the projections with sets P1 and P2 is driven by the wide range for the average time (1/τ) needed to acquire resistance when infected and using PrEP (between six months and never), unrestricted or weakly-restricted access to PrEP by infected individuals, and irreversible resistance status after PrEP is interrupted. This allows for accumulation of a substantial number of infected individuals using PrEP who in some scenarios quickly acquire persistent resistance, while in others may never develop ADR. Conversely, when the infected users are quickly removed from PrEP and the reversal of drug resistance back to wild-type does not take long, the influence of resistance on the intervention outcomes remains low (sets P4 and P5) under all epidemic conditions.

When is drug resistance beneficial?

The projections of our model with different parameter sets suggest that the possibility for the resistance to contribute positively to PrEP effectiveness (Fig. 2D, P1–4) is utilized by two modeling assumptions: i) the influence of the reduced viral fitness of the drug-resistant HIV on its ability to be effectively transmitted and ii) the loss of PrEP protection due to an exposure to drug-resistant compared to wild-type HIV, which act in opposite directions. The loss of viral fitness lowers the infectiousness of the carriers of resistance (relative infectiousness $\beta_r$) and indirectly increases the effectiveness of PrEP, while the reduced PrEP efficacy against resistant HIV (relative PrEP efficacy $\gamma_r$) decreases the number of infections prevented due to PrEP, and as a result decreases the effectiveness of the interventions. Parameter sets, which assume that the PrEP efficacy is the same against resistant and non-resistant HIV ($\gamma_r = 1$) and that resistance carriers are significantly less infectious ($\beta_r \leq 0.5$), predict positive contribution of the resistance to CPF (Fig. 2D, P1–P3). A negative resistance contribution to CPF (Fig. 2D, P5–P7) is observed when a relatively low PrEP efficacy against resistant HIV ($\gamma_r \leq 0.5$) is combined with a small fitness cost of resistance ($\beta_r \geq 0.5$).

We study further the impact of relative infectiousness ($\beta_r$) and relative PrEP efficacy ($\gamma_r$) on the relative CPF with the rest of the resistant parameters fixed (Fig. 3A) or varied in their ranges from Table 2 (Fig. 3B). This analysis confirms that the resistance is more likely to be beneficial in terms of CPF if the infectiousness of drug resistance carriers is substantially reduced (relative infectiousness below 50%) compared to the wild-type HIV carriers. If PrEP provides the same protection against resistant and wild-type HIV (relative efficacy equals one), then resistance always improves the CPF independently of relative infectiousness of the infected with resistant HIV. Overall, resistance has negative effects on CPF only if PrEP is substantially less effective against resistant HIV, and resistance carriers are almost as infectious as wild-type carriers (shaded region in Fig. 3A and blue region in Fig. 3B). The perfect alignment between these regions and the clear separation between blue and red plots in Fig. 3B suggest that the impact of the remaining resistance parameters on the relative CPF is negligible. Therefore, the combination of relative infectiousness and relative efficacy used in a mathematical model could be a good predictor of whether the inclusion of resistance increases or reduces the projected PrEP effectiveness. The median values of the relative infectiousness and efficacy from the published studies plotted in Fig. 3A are sufficient to correctly predict the direction of resistance contribution (positive for P1–P4 and negative for P5–P7) when corresponding parameter sets are used (Fig. 2D).

Sensitivity analysis

The partial rank correlation coefficients (PRCC) between resistance parameters and intervention outcomes (relative CPF and resistance prevalence after ten years) are presented in Figure 4. It clearly confirms the observation from the previous section that only the relative PrEP efficacy against resistant HIV and relative infectiousness of the resistance carriers have a strong impact on the monotonicity of the relative ten-year CPF. The restriction of the PrEP use by infected individuals and the resistance reversion rate are among the key factors, negatively correlated with the resistance prevalence. Not surprisingly, the rate to develop resistance while infected and using PrEP is the strongest driver of the expected resistance prevalence and therefore needs to be carefully monitored when a particular PrEP intervention is rolled out.

Discussion

Possible spread of drug-resistance due to the availability of PrEP is a major public health concern when deciding to include PrEP in HIV prevention programs. In this study we simulated and objectively compared the influence of different resistance assumptions on the predicted population-level impact of PrEP. We have borrowed PrEP resistance profiles from previously published modeling studies and tested the extracted parameter sets under identical epidemic conditions and intervention scenarios. This analytic approach allowed us to assess the impact of each resistance assumption on intervention outcomes in order to guide the interpretation of these in further studies. We found that a wide range of resistance prevalence (from 1% to almost 50%) may be expected after ten years of PrEP use if 50% effective PrEP is consistently used by 50% of the population (Fig. 2B). The spread of resistance may contribute both negatively (up to 10%) or positively (up to 30%) to the projected PrEP effectiveness, depending on what resistance parameterization has been used (Fig. 2D).
From a public-health perspective our analysis implies that the influence of resistance should not be neglected. The large impact projected under scenarios with weak control on the access to PrEP by infected individuals and slow reversion back to wild-type after PrEP is interrupted suggests that PrEP users have to be carefully monitored in future community interventions. Modeling studies which do not address the emergence of resistance not only underestimate the risk, but may predict PrEP impact at significantly different levels compared to analyses in which resistance is included (up to 30% under some of the extracted sets of resistance assumptions). Although we are not in a position to recommend or reject any specific resistance-handling setups, we would like to point out the critical importance of the way resistance is incorporated in the modeling studies.

Many different factors should be considered when the mechanisms of emergence and persistence of drug-resistance due to PrEP are analyzed. We identified two of them: the decreased PrEP efficacy against resistant HIV, and the reduction in HIV fitness (decreased infectiousness of resistance carriers), which in combination may serve as a predictor if whether drug resistance will add to the projected PrEP effectiveness (Fig. 3). Although under no conditions should the spread of resistant HIV be considered a positive outcome, this result is informative, for the efforts to resolve the problems with resistance may improve or reduce the overall impact of the intervention. More empirical data is needed to obtain better estimates of those parameters for the promising PrEP candidates.

Several simplifying assumptions, made in the model, may influence the presented results. For instance, the contribution of resistance is amplified by the reduced infectiousness of PrEP users applied in the model. This assumption, incorporated in four of the published studies [19,21,23,25], is based on the expected lower viral load of individuals who become infected while using PrEP (breakthrough infections). Modeling the adherence to PrEP present additional difficulties because the effects of the inconsistent PrEP use on the PrEP efficacy and the rate of resistance emergence is unclear. Our simplifying assumption of perfect adherence avoids these uncertainties but may overestimate the projected impact of PrEP. However, it does not affect the comparison of the extracted sets of resistance assumptions since we use the resistance rates from the published papers which correspond to perfect adherence. The epidemic conditions, intervention assumptions, the structure and complexity of the model, and the sampling methods of the input parameters used in our analysis differ from the original studies. Therefore, the results reported are not comparable to those reported in the previously published papers and are representative of the extracted sets of resistance assumptions only.

This analysis presents a novel approach of identifying and investigating the importance of specific mechanisms and assumptions to the impact evaluations based on mathematical models. Our findings invite extensive communication between modelers and virologists toward clarifying the set of resistance assumptions biologically relevant to the PrEP products which are already in use or may be soon added to the arsenal against HIV. We should reiterate that our projections are related to resistance due to PrEP only and do not track resistance from other sources, such as failing ART. It is possible that the carriers of PrEP resistance may have increased chance to fail ART when initiated if PrEP and ART used at the same location share active components. Therefore, the increasing number of people using PrEP should be closely monitored and all breakthrough infections should be tested for drug-resistance. Data on the rates of resistance development, reversion of resistance, fitness loss of the drug-resistant HIV and rates of failing ART among those who become infected while using PrEP is critically needed to improve the accuracy of the resistance projections obtained through mathematical models.

Supporting Information

File S1. Supporting Information (DOCX)

Acknowledgments

The authors are grateful to Kathy Mack, Administrative Assistant at the Vaccine & Infectious Disease Division of the Fred Hutchinson Cancer Research Center for editing of the manuscript.

The authors thank the anonymous referee for many useful comments on an earlier draft.

Author Contributions

Conceived and designed the experiments: DD MCB TBH. Performed the experiments: DD. Analyzed the data: DD MCB ERB TBH. Contributed reagents/materials/analysis tools: DD MCB ERB TBH. Wrote the paper: DD MCB ERB TBH.

References

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine 363: 2587–2599.

2. Abdoel Karim Q, Abdoel Karim S, Frohlich J, Grohler A, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women, Science 329:5996: 1168-1174.

3. Centers of Disease Control and Prevention (2011) CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection among Heterosexuals, Press Release. Available: http://www.cdc.gov/nchhstp/newsroom/2012/PrEPHeterosexualGuidance-PressRelease.html. Accessed 04 January 2013.

4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 55). Vaccine & Infectious Disease Division of the Fred Hutchinson Cancer Research Center for editing of the manuscript.

5. FHI (2011) FHI Statement on the FEM-PrEP HIV Prevention Study, FHI360, Press Release. Available: http://www.fhi360.org/en/AboutFHI/Media/Releases/FEM-PrEPStatement041811.htm. Accessed 04 January 2013.

6. Jeanne Marrazzo GR, Nair G, Palanne T, Mkhize B, Nakihono G, et al. (2013) Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections, Atlanta, GA.

7. Food and Drug Administration (2012) FDA approves first drug for reducing the risk of sexually acquired HIV infection, Press Release. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 04 January 2013.

8. Centers of Disease Control and Prevention (2011) Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. Morbidity and Mortality Weekly Report 60(03): 63–68.

9. Centers of Disease Control and Prevention (2012) CDC Issues Interim Guidance on Use of Medication to Prevent HIV Infection among Heterosexually Active Adults, Press Release. Available: http://www.cdc.gov/nchhstp/newsroom/2012/PrEPHeterosexualGuidance-PressRelease.html. Accessed 04 January 2013.

10. The Consensus Committee, Southern African HIV Clinicians Society, chaired by Linda-Gail Bekker and Kevin Rebe (2012) Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection, Southern African Journal of HIV Medicine 13 (2): 40-53.

11. Karmen E, Potts M, Getz WM (2003) Microbicides and HIV: Help or hindrance? JAIDS 34: 71–75.

12. Bresan R, McGowan I, Topaz C, Schwartz EJ, Anton P, et al. (2006) Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering 3: 459–466.

13. Chen F (2006) The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 20: 1551-1553.

14. Vickersen P, Watts G, Delany S, Alary M, Ress H, et al. (2006) The importance of context: Model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sexually Transmitted Diseases 33: 397–405.
23. Dimitrov DT, Masse B, Boily MC (2010) Who Will Benefit from a Wide-Scale
22. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B (2010) Evaluating the
20. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009)
19. Wilson DP, Coplan PM, Wainberg MA, Blower SM (2008) The paradoxical
18. Vickerman PD, Foss AP, Watts CP (2008) Using Modeling to Explore the
17. Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ
16. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling
15. Abbas UL, Anderson RM, Mellors JW (2007) Potential Impact of Antiretroviral
14. Cox AP, Foss AM, Shafer LA, Nsubuga RN, Vickerman P, et al. (2011)
13. Barditch-Crovo P, Deeks SG, Collier A, Sabin S, Coaleff DE, et al. (2001)
12. The HIV Modelling Consortium (2011) The Potential for the Spread of Drug
11. Statistics South Africa (2010) Mid-year population estimates. Available: http://
10. Williams BG, Karim SSA, Karim QA, Gouws E (2011) Epidemiological Impact
9. Prada N, Davis B, Jean-Pierre P, La Roche M, Duh FM, et al. (2008) Drug-
8. Vissers DCJ, Boily MC, Dimitrov D, Karim Salim SA, Masse B (2011) The future role of
7. Supervie V, Garcia-Lema JG, Heneine W, Blower S (2010) HIV, transmitted
drug resistance, and the paradox of preexposure prophylaxis. Proceedings of
6. The National Academy of Sciences of The United States of America 107:
5. Baggaley RF, Wang L, Masse B, Boily MC (2010) Who Will Benefit from a Wide-Scale
4. Abbas UL, Hood G, Wetzel AW, Mellors JW (2011) Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP). PLoS ONE 6:e10185
3. Dimitrov DT, Masse B, Boily MC (2010) The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention. SEXUALLY TRANSMITTED INFECTIONS 87(7): 646–653
2. Hallett TB, Barten JM, Helfron R, Barnabas R, de Bruyn G, et al. (2011) Optimal Uses of Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South Africa: A Modelling Study. Plos Medicine 8:e100123
1. Williams BG, Karim SSA, Karim QA, Gouws E (2011) Epidemiological Impact of Tenofovir Gel on the HIV Epidemic in South Africa. Jaids-Journal of AIDS and HIV Infection 22: 1829–1839

Influence of Resistance Assumptions on PrEP Impact